AN EXPERT
IS BORN OUT OF DEEP FOCUS

We are committed to continuously improving the quality of life of patients with lung diseases by solving the technical problems of pulmonary drug delivery.
Over the years, Chenpon has continuously innovated in the field of pulmonary drug delivery and now possesses comprehensive research and development capabilities in designing highly complex inhalation devices, superfine powder manufacturing, and in vitro performance testing.
With rich experience in the registration, production and commercialization of domestic and international pharmaceutical products, Chenpon can provide professional technical services and overall solutions for product development for pulmonary drug delivery.
Formulation Development Platform

Key to the successful development of dry powder inhalation products lies in the balanced control of the physicochemical properties of the active ingredients and excipients, as well as the adhesion and cohesion, and the adhesion and separation processes. 

DPI Device Development Platform

Wide drug-loading range, precise dispensing and accurate drug delivery capabilities, simple and intuitive use, and the ability to be commercially produced at low cost.

With our device development capabilities, we are capable of provide services for various formulations, including drug dispensing and delivery, appearance and usability study from a human factors perspective, and industrial considerations such as large-scale production and assembly.

PATENTS
Chenpon currently holds 84 patents, including 32 patents in the inhalation technological areas. Among those, 16 have been granted.
1
US Patent
15
International and Domestic Awards
62
Certificates of Honor
84
Patents
PIPELINE
Chenpon advances the research and development of innovative drug delivery through investment, thereby creating a dynamic and competitively innovative product development pipeline.
AREAS OF FOCUS
Our core therapeutic areas include asthma, chronic obstructive pulmonary disease, pulmonary arterial hypertension, pulmonary fibrosis, essential tremor, and more. We explore various more precise and effective drug delivery solutions, and our research may change the way these diseases are treated.
  • Asthma
    Globally, there are approximately 300 million asthma patients.
  • Chronic Obstructive Pulmonary Disease
    Globally, there are about 350 million COPD patients.
  • Pulmonary Arterial Hypertension
    Globally, there are approximately 70 million patients.
  • Essential Tremor
    The prevalence is about 4.6% in people over 65 years of age.